<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00842140</url>
  </required_header>
  <id_info>
    <org_study_id>HCRP15811/2005</org_study_id>
    <nct_id>NCT00842140</nct_id>
  </id_info>
  <brief_title>Safety of Hormonal Contraceptives Therapies in Polycystic Ovary Syndrome (PCOS) Women</brief_title>
  <official_title>Metabolic Effects of Multiple Therapies in Polycystic Ovary Syndrome (PCOS) Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Sao Paulo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Sao Paulo</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study to assess early markers of cardiovascular disease in women with
      polycystic ovary syndrome in use of oral contraceptive containing ethynilestradiol and
      chlormadinone acetate alone or associated with Spironolactone.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Polycystic ovary syndrome (PCOS) is associated with comorbidities that may contribute to
      increased risk of cardiovascular disease (CVD). Oral contraceptives (OC) have been the
      mainstay of PCOS pharmacological therapy for decades. However, in non-hyperandrogenic women,
      OC use is associated with higher risk of cardiovascular disease, raising concern about a
      possible worsening of the unfavorable metabolic and cardiovascular profile of PCOS patients.
      There is lack of evidence about the impact of PCOS pharmacological therapies on
      cardiovascular risk markers and the long-term safety of these drugs in PCOS has not been
      established. The aim of this study is to compare the effect of an OC alone or associated with
      an anti-androgenic drug (spironolactone) on echografic cardiovascular risk markers, metabolic
      and hemostatic variables.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2006</start_date>
  <completion_date type="Actual">January 2009</completion_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To compare the effect of an oral contraceptive alone or associated with an anti-androgenic drug (spironolactone) or associated with metformin on echografic cardiovascular risk markers.</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>to compare the effect of an oral contraceptive alone or associated with an anti-androgenic drug (spironolactone) or associated with metformin on seric cardiovascular risk markers.</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>to compare the effect of an oral contraceptive alone or associated with an anti-androgenic drug (spironolactone) or associated with metformin on hemostatic variables.</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>to compare the effect of an oral contraceptive alone or associated with an anti-androgenic drug (spironolactone) or associated with metformin on metabolic variables.</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">75</enrollment>
  <condition>Polycystic Ovary Syndrome</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group will receive an oral contraceptive containing 0,03mg ethynylestradiol and 2mg chlormadinone acetate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patient will receive an oral contraceptive (0,03mg ethynylestradiol and 2mg chlormadinone acetate) plus 100 mg spironolactone. One pill each once a day for twelve months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patient will receive an oral contraceptive (0,03mg ethynylestradiol and 2mg chlormadinone acetate) plus 850 mg metformin.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oral contraceptive</intervention_name>
    <description>oral contraceptive (0,03mg ethynylestradiol and 2mg chlormadinone acetate)once a day for 12 months</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Belara</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral contraceptive plus spironolactone</intervention_name>
    <description>The patient will receive an oral contraceptive (0,03mg ethynylestradiol and 2mg chlormadinone acetate) plus 100 mg spironolactone. One pill each once a day for twelve months.</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Belara</other_name>
    <other_name>Spironolactone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral contraceptive plus metformin</intervention_name>
    <description>Oral contraceptive (0,03mg ethynylestradiol and 2mg chlormadinone acetate) plus 850 mg of metformin</description>
    <arm_group_label>3</arm_group_label>
    <other_name>Belara</other_name>
    <other_name>Metformin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age between 18 and 35 years

          -  diagnosis of PCOS by Rotterdam Consensus

        Exclusion Criteria:

          -  smoking, alcoholism, drug addiction;

          -  current pregnancy;

          -  current or previous use (up to two months before the study) of oral, vaginal, monthly
             injectable, or transdermal combined hormonal contraceptives;

          -  current or previous use (up to six months before the study) of a long-lasting hormonal
             contraceptive method (injectable, implant, or intrauterine device);

          -  antiandrogenic or hypoglycemic drugs, anti-inflammatory drugs, or statins;

          -  presence of systemic diseases (DM2, cardiovascular disease, autoimmune diseases, liver
             disease, thyroid disease, or congenital renal hyperplasia);

          -  personal history of arterial or venous thrombosis; chronic or acute inflammatory
             processes;

          -  puerperium of 12 weeks or less
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rui A Ferriani, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>University of Sao Paulo</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marcos Felipe S de Sa, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Sao Paulo</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carolina S Vieira, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Sao Paulo</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Sao Paulo</name>
      <address>
        <city>Ribeirao Preto</city>
        <state>Sao Paulo</state>
        <zip>14049-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>February 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 10, 2009</study_first_submitted>
  <study_first_submitted_qc>February 10, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 12, 2009</study_first_posted>
  <last_update_submitted>July 21, 2010</last_update_submitted>
  <last_update_submitted_qc>July 21, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 22, 2010</last_update_posted>
  <responsible_party>
    <name_title>Rui Alberto Ferriani</name_title>
    <organization>University of Sao Paulo</organization>
  </responsible_party>
  <keyword>Polycystic ovary syndrome</keyword>
  <keyword>Oral Contraceptives, Hormonal</keyword>
  <keyword>Cardiovascular Disease</keyword>
  <keyword>Endothelium</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Contraceptive Agents</mesh_term>
    <mesh_term>Chlormadinone Acetate</mesh_term>
    <mesh_term>Contraceptives, Oral</mesh_term>
    <mesh_term>Spironolactone</mesh_term>
    <mesh_term>Ethinyl Estradiol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

